Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Aptose Biosciences Inc

Healthcare CA APS

2.2CAD
0.00(0%)

Last update at 2026-06-03T19:37:00Z

Day Range

2.192.20
LowHigh

52 Week Range

1.023.21
LowHigh

Fundamentals

  • Previous Close 2.20
  • Market Cap5.97M
  • Volume500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-24.70100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-14.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -25.91383M -25.43000M -51.20700M -41.82300M -65.35400M
Minority interest - - - - -
Net income -25.91383M -25.43000M -51.20700M -41.05300M -65.26200M
Selling general administrative - 11.15M 15.59M 14.43M 19.32M
Selling and marketing expenses - - - - -
Gross profit -0.42532M - -0.47454M - -
Reconciled depreciation - 0.40M 0.47M 0.53M 0.62M
Ebit -25.15579M -26.25700M -52.35600M -42.59300M -65.44600M
Ebitda -24.73047M -26.22500M -52.26800M -42.06500M -64.82400M
Depreciation and amortization 0.43M 0.03M 0.09M 0.53M 0.62M
Non operating income net other - - - - -
Operating income -25.15579M -26.25700M -52.35600M -42.59300M -65.44600M
Other operating expenses 25.16M 26.26M 52.36M 42.60M 65.45M
Interest expense 0.86M -0.20700M 0.00000M 0.77M 0.09M
Tax provision - - - - -
Interest income - 0.36M 1.15M 0.78M 0.09M
Net interest income - 0.15M 1.15M 0.79M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -0.77000M -0.09200M
Total revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 24.73M 26.26M 52.36M 42.60M 65.45M
Cost of revenue 0.43M - 0.47M - -
Total other income expense net -0.75804M 0.83M 1.15M 0.77M 0.09M
Discontinued operations - - - - -
Net income from continuing ops - -25.43000M -51.20700M -41.82300M -65.35400M
Net income applicable to common shares - - - -41.82300M -65.35400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.99M 10.13M 12.99M 51.03M 82.53M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.35M 0.57M 0.60M 0.26M 0.13M
Total liab 37.11M 14.67M 15.89M 13.29M 8.29M
Total stockholder equity -27.11756M -4.54300M -2.90100M 37.74M 74.24M
Deferred long term liab - - - - -
Other current liab 9.10M - 11.38M 5.66M 6.02M
Common stock 458.93M - 444.81M 437.52M 437.39M
Capital stock - 457.40M 444.81M 437.52M 437.39M
Retained earnings -565.40417M -540.96700M -515.53700M -464.33000M -422.50700M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 4.09M 6.15M 9.25M 36.97M 39.11M
Cash and equivalents - - - 36.37M 38.82M
Total current liabilities 9.29M 4.46M 15.27M 12.28M 8.17M
Current deferred revenue - - - - -
Net debt 23.93M 3.87M -8.23700M -35.66700M -38.54000M
Short term debt 0.19M - 0.39M 0.30M 0.46M
Short long term debt - - - - -
Short long term debt total 28.01M - 1.01M 1.30M 0.57M
Other stockholder equity 83.66M - 72.15M 68.87M 63.67M
Property plant equipment - - - 1.51M 0.79M
Total current assets 6.43M 9.53M 11.89M 49.52M 81.74M
Long term investments - - - - -
Net tangible assets - - - - 74.24M
Short term investments - - 0.00000M 9.99M 40.01M
Net receivables - - - - -
Long term debt - 10.02M - - -
Inventory - - - - -
Accounts payable - 1.26M 3.49M 6.33M 1.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.30814M - -4.31600M -4.31800M -4.31600M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.38M - - - -
Deferred long term asset charges - - - - -
Non current assets total 3.56M 0.60M 1.09M 1.51M 0.79M
Capital lease obligations - 0.62M 1.01M 1.30M 0.57M
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.02M 9.96M 30.07M -34.99600M
Change to liabilities - - - 0.00000M -0.47200M
Total cashflows from investing activities - 0.02M 9.96M 30.07M -35.20800M
Net borrowings - 10.00M 0.00000M - -
Total cash from financing activities 19.72M 33.41M 6.91M 0.12M 0.23M
Change to operating activities - - - - 1.43M
Net income -25.91383M -25.43000M -51.20700M -41.82300M -65.35400M
Change in cash -2.93568M -2.54500M -27.71800M -2.14400M -78.27900M
Begin period cash flow 7.02M 9.25M 36.97M 39.11M 117.39M
End period cash flow 4.09M 6.71M 9.25M 36.97M 39.11M
Total cash from operating activities -22.37495M -35.97700M -44.59000M -32.32200M -43.30400M
Issuance of capital stock - 23.41M 6.88M 0.10M 0.04M
Depreciation 0.43M 0.40M 0.47M 0.53M 0.62M
Other cashflows from investing activities - 0.02M - 30.09M -34.99600M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 0.03M - 0.12M 0.23M
Other cashflows from financing activities - 0.03M 0.03M 0.01M 0.19M
Change to netincome - - - - 20.47M
Capital expenditures 0.00000M 0.00500M 0.03M 0.02M 0.21M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.74M -11.02500M 2.81M 4.32M 1.52M
Stock based compensation - 1.06M 3.65M 5.21M 12.95M
Other non cash items 1.38M -0.98600M -0.18700M -0.55100M 6.96M
Free cash flow -22.37495M -35.98200M -44.61900M -32.34600M -43.51600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APS
Aptose Biosciences Inc		 - -% 2.20 - - 3234.43 91.24 4817.86 0.07
EPRX
Eupraxia Pharmaceuticals Inc		 -0.38 4.11% 8.87 - - - 8.45 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -1.04 7.56% 12.72 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -1.36 14.06% 8.31 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 0.02 1.28% 1.58 - 3.87 4263.36 9.74 4422.35 -6.3589

Reports Covered

Stock Research & News

View All

Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Inc

66 Wellington Street West, Toronto, ON, Canada, M5K 1E6

Key Executives

Name Title Year Born
Dr. William G. Rice Ph.D. Chairman, Pres, CEO & Chief Accounting Officer 1959
Dr. Rafael Bejar M.D., Ph.D. Sr. VP & Chief Medical Officer 1972
Ms. Janet Clennett C.A. VP of Fin. NA
Mr. Fletcher Payne Sr. VP & CFO 1963
Mr. Roger Davies B.Sc. VP of Operations NA
Mr. Philippe Ledru Sr. VP & Chief Commercial Officer NA
Dr. William G. Rice Ph.D. Chairman, President & CEO 1959
Mr. Fletcher Payne Senior VP, CFO, Chief Business Officer & Secretary 1963
Dr. Rafael Bejar M.D., Ph.D. Senior VP & Chief Medical Officer 1972
Dr. Marc Wiles Ph.D. Senior Vice President of Regulatory Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions